Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. Click for a PRME update.
CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.
Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.
Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.
View interactive chart, options flow, and AI analysis for EDIT on Zorveq Finance.
Open EDIT Chart & Analysis →